ArticleBMC pediatrics2025
Gut microbiome dysbiosis as a potential biomarker for liver metabolic disorders in in neonatal hemolytic jaundice.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intervention WithFood science & nutrition · 2026Article
- Platelet-Rich Plasma Attenuates Knee Osteoarthritis in Rats via Modulation of Gut Microbiota.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aims to reveal the composition and features of the gut microbiota in neonatal hemolytic jaundice, potentially identifying biomarkers for the diagnosis of this condition.
methodsA total of 62 neonates with hemolytic jaundice and 20 healthy neonates were ultimately enrolled in the study. Clinical data and fecal samples from these infants were collected separately. The composition and features of the gut microbiota were analyzed using 16S rRNA high-throughput sequencing technology. Alpha and Beta diversity analyses were conducted to elucidate the differences in gut microbiota composition. Additionally, LEfSe analysis was employed to identify differential microorganisms. Finally, PICRUSt2, metagenomeSeq, and BugBase software were utilized to investigate the phenotypic and functional differences in the gut microbiota.
resultsBeta diversity analysis revealed significant differences in the composition of gut microbiota. LEfSe analysis demonstrated a significant increase in the relative abundance of Enterobacter in neonatal hemolytic jaundice. Furthermore, METACYC metabolic pathway analysis based on PICRUSt2 indicated a notable elevation in liver-related metabolic pathways in neonatal hemolytic jaundice. The metabolic analysis of differential bacterial genera revealed that Enterobacter secretes a wide array of enzymes, including oxidases, oxidoreductases, transferases, hydrolases, isomerases, and lyases. Notably, these enzymes are responsible for altering the liver metabolic pathways in neonates with hemolytic jaundice.
conclusionsEnterobacter is linked to multiple metabolic pathways in the liver via the secretion of numerous enzymes along the gut-liver axis metabolic pathway. This interaction indirectly reflects the metabolic status and disease progression in neonatal hemolytic jaundice. Consequently, Enterobacter may serve as a potential diagnostic marker of the gut microbiota for assessing liver metabolic disorders associated with hemolytic jaundice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.